Emergent BioSolutions

(NYSE) EBS

Current Price$8.51

Market Cap$441.04M

Since IPO (2006)-22%

5 Year-86%

1 Year+66%

1 Month+4%

Emergent BioSolutions Financials at a Glance

Market Cap

$441.04M

Revenue (TTM)

$676.80M

Net Income (TTM)

$8.60M

EPS (TTM)

$-0.28

P/E Ratio

-30.20

Dividend

$0.00

Beta (Volatility)

1.78 (High)

Dividend

$0.00

Beta (Volatility)

1.78 (High)

Price

$8.51

Volume

172

Open

$8.38

Price

$8.51

Volume

172

Open

$8.38

Previous Close

$8.54

Daily Range

$8.25 - $8.63

52-Week Range

$4.71 - $14.06

Dividend

$0.00

Beta (Volatility)

1.78 (High)

Price

$8.51

Volume

172

Open

$8.38

Previous Close

$8.54

Daily Range

$8.25 - $8.63

52-Week Range

$4.71 - $14.06

EBS News

Page 1

EBS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Emergent BioSolutions

Industry

Biotechnology

Sector

Health Care

Employees

900

CEO

Joseph C. Papa, MBA

Website

www.emergentbiosolutions.com

Headquarters

Gaithersburg, MD 20879, US

EBS Financials

Key Financial Metrics (TTM)

Gross Margin

44%

Operating Margin

11%

Net Income Margin

-1%

Return on Equity

-2%

Return on Capital

Return on Assets

-1%

Earnings Yield

-3.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$441.04M

Shares Outstanding

51.64M

Volume

172

Avg. Volume

863.05K

Financials (TTM)

Gross Profit

$350.60M

Operating Income

$110.20M

EBITDA

$208.50M

Operating Cash Flow

$170.60M

Capital Expenditure

$13.80M

Free Cash Flow

$156.80M

Cash & ST Invst.

$205.40M

Total Debt

$572.10M

Emergent BioSolutions Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$156.10M

-29.7%

Gross Profit

$67.60M

-42.0%

Gross Margin

43.31%

N/A

Market Cap

$441.04M

N/A

Market Cap/Employee

$490.05K

N/A

Employees

900

N/A

Net Income

$6.80M

-90.0%

EBITDA

$34.60M

-53.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$413.30M

+20.0%

Accounts Receivable

$121.60M

-40.3%

Inventory

$327.60M

+4.3%

Long Term Debt

$573.60M

-13.8%

Short Term Debt

$0.00

N/A

Return on Assets

-0.65%

N/A

Return on Invested Capital

6.08%

N/A

Free Cash Flow

$36.20M

-144.6%

Operating Cash Flow

$33.80M

-201.8%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AQSTAquestive Therapeutics, Inc.

AQSTAquestive Therapeutics, Inc.$4.22+0.48%

SNDLSNDL Inc.

SNDLSNDL Inc.$1.42+0.71%

RIGLRigel Pharmaceuticals, Inc.

RIGLRigel Pharmaceuticals, Inc.$29.54+0.48%

SIGASIGA Technologies, Inc.

SIGASIGA Technologies, Inc.$4.63+0.65%

ORGOOrganogenesis Holdings Inc.

ORGOOrganogenesis Holdings Inc.$2.56-0.39%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$10.79+1.41%

ESPREsperion Therapeutics, Inc.

ESPREsperion Therapeutics, Inc.$3.12+0.32%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$64.91-0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$13.18+0.01%

NOKNokia

NOKNokia$13.14-0.01%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$50.51+0.01%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$45.40+0.02%

XNDUXanadu Quantum Technologies

XNDUXanadu Quantum Technologies$13.99-0.61%

BBBlackBerry

BBBlackBerry$5.58+0.03%

Questions About EBS

What is the current price of Emergent BioSolutions?

Emergent BioSolutions is trading at $8.54 per share.

What is the 52-week range for Emergent BioSolutions?

Over the past 52 weeks, Emergent BioSolutions has traded between $4.71 and $14.06.

How much debt does Emergent BioSolutions have?

As of the most recent reporting period, Emergent BioSolutions reported total debt of $635.00M.

How much cash does Emergent BioSolutions have on hand?

Emergent BioSolutions reported $161.50M in cash and cash equivalents in its most recent financial results.

What is Emergent BioSolutions’s dividend yield?

Emergent BioSolutions does not currently have a dividend yield.

Emergent BioSolutions

Emergent BioSolutions Financials at a Glance

EBS News

Best Vaccine Stocks of 2026: Are They Right for Your Portfolio?

Why Emergent BioSolutions Stock Blasted Higher Today

Why Emergent BioSciences Stock Plummeted Today

Why Emergent BioSolutions Stock Is Skyrocketing Today

Why Emergent BioSolutions Stock Is Tumbling Today

Why Emergent BioSolutions Stock Dived by 9% Today

Better Recovery-Story Buy: Emergent BioSolutions or Invitae?

Is Emergent BioSolutions Stock a Buy Now?

EBS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Emergent BioSolutions

EBS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Emergent BioSolutions Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About EBS

What is the current price of Emergent BioSolutions?

What is the 52-week range for Emergent BioSolutions?

How much debt does Emergent BioSolutions have?

How much cash does Emergent BioSolutions have on hand?

What is Emergent BioSolutions’s dividend yield?

Premium Investing Services